IMRN logo

IMRN Immuron Limited

NASDAQ Capital Market · Biotechnology · Healthcare

$0.85
-0.02 (-1.89%)

Immuron Limited, an Australian biopharmaceutical firm founded in 1994 and headquartered in Carlton, is dedicated to the exploration, advancement, and worldwide commercialization of polyclonal antibodies. Operating across two divisions—Research and Development, and Hyperimmune Products—the company serves markets in Australia, Israel, Canada, the United States, and other international regions. Its c…

Market Cap: $6.86Mwww.immuron.com.au

Price

No data yet.

Social Signal Score

56
5d
—
30d
60
2 mentions
—
60d
55
4 mentions
—
90d
54
5 mentions
—
news: 5

Analyst Ratings

1 analyst
Buyconsensus
Strong Buy 0Buy 1Hold 0Sell 0Strong Sell 0

Revenue

$3.58M+2343.84%
$-10.7K$1.36M$2.73M$4.11M
Jun 2008Jun 2026

Analyst Estimates

FY2025
$-0.04
$-0.04–$-0.04
1 analysts
FY2026
$-0.01
$-0.01–$-0.01
1 analysts
FY2027
$-0.01
$-0.01–$-0.01
1 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Steven George Lydeamore
Sector
Healthcare
Industry
Biotechnology
Employees
7
Beta
0.51
Country
AU
Piotroski score
4 / 9 (Middling)
Altman Z-score
-5.66
www.immuron.com.au